Biogen Message Board - Msg: 4943928

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 181.89

0.0%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (671)	6/20/1998 2:26:00 AM
From: Vector1	Read Replies (1) of 1686

Harold, Thanks for the excellent report on the shareholder meeting. I agree that Biogen is one of the best run, if not the best run biotech. With the Intron A patent litigation settled and Schering pushing Intron A into new indications it looks like the royalty stream will decline much less quickly than had been expected by some on the street. If second quarter Avonex sales are strong (north of 85m) we could be looking at a drive into the mid 50s. <<they said Idec Pharmaceutical's travelling down the CD40L path would be an expensive trip.>> Interesting. A little swagger in that statement. Biogen is a veteran of numerous patent wars. I bet they are well prepared to take on IDEC. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next